Previous 10 | Next 10 |
Cardiol Therapeutics is developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company’s lead candidate CardiolRx is an ultra-pure, high concentration cannabidiol oral formulation. The US FDA has cleared the company’s IND f...
Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, an...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...
Cardiol Therapeutics (NASDAQ:CRDL) priced its public offering of 16.35M units at $3.07/unit for gross proceeds of ~$50.19M. Each Unit will consist of one class A common share and 0.5 warrant. Each warrant can be used to buy one common share at $3.75 per warrant share. The company intends to u...
Urban One (NASDAQ:UONEK) -42%. The OLB Group (NASDAQ:OLB) -20% following $25M stock and warrants private offering Playtika Holding (NASDAQ:PLTK) -17% on Q3 earnings release Zillow Group (NASDAQ:Z) -15% on Q3 earnings release Tupperware Brands (NYSE:TUP) ...
Cardiol Therapeutics Announces Pricing of Public Offering of Units Canada NewsWire OAKVILLE, ON , Nov. 3, 2021 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stage biotechnology company ...
Cardiol Therapeutics (NASDAQ:CRDL) trades 6.2% down after hours on filing a preliminary prospectus supplement to its short form base shelf prospectus related to a proposed public offering of units. Each unit consists of one Class A common share and one-half of one Class A commo...
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Canada NewsWire OAKVILLE, ON , Nov. 2, 2021 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stag...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, Canadian clinical-stage biotech company Cardiol Therapeutics (NASDAQ: CRDL ) is seeing impressive investor interest although the biotech firm closed down about 2%. However, CRDL stock has been a big mover ...
Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular di...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...